BioNexus Gene Lab (NASDAQ: BGLC) taps new CCO to drive Fidelion VitaGuard MRD commercialization

Rhea-AI Filing Summary

BioNexus Gene Lab Corp. appointed Dr. Muthu Meyyappan as Chief Commercial Officer of its affiliate Fidelion Diagnostics in connection with the Fidelion transaction. Fidelion is the international commercialization and intellectual property vehicle for the VitaGuard™ minimal residual disease liquid biopsy platform developed by Tongshu Gene.

Dr. Meyyappan will lead Fidelion’s global commercial strategy and partnerships to drive adoption of advanced oncology diagnostic technologies. BioNexus holds exclusive rights to commercialize VitaGuard™ across Southeast Asia through a licensing arrangement with Fidelion, supporting its strategy to expand access to precision oncology diagnostics in the region.

EXHIBIT 99.1

FOR IMMEDIATE RELEASE

BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of its VitaGuard™ MRD Platform

KUALA LUMPUR, MALAYSIA – March 11, 2026

BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Fidelion is a precision diagnostics company focused on advancing next-generation oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays. Fidelion serves as the international intellectual property and commercialization vehicle for the VitaGuard™ MRD technology developed by Tongshu Gene, supporting commercialization initiatives outside Greater China. BGLC is a strategic investor in Fidelion and holds the exclusive commercialization rights for VitaGuard™ throughout Southeast Asia through its licensing arrangement with Fidelion.

Dr. Meyyappan will lead Fidelion’s global commercial strategy and partnerships, including the development of clinical, laboratory, and pharmaceutical collaborations to support the adoption of advanced oncology diagnostic technologies across international markets.

Minimal residual disease (MRD) testing represents one of the fastest-growing segments of precision oncology diagnostics, as healthcare systems increasingly adopt genomic technologies to detect cancer recurrence earlier and guide more personalized treatment monitoring.

Experienced Commercial Leader in Oncology Diagnostics

Dr. Meyyappan brings more than 15 years of global leadership experience in precision oncology diagnostics, genomics, and liquid biopsy commercialization.

He previously held senior commercial leadership roles at Menarini Silicon Biosystems, Congenica, Variantyx, and QIAGEN, where he worked on the commercialization and global expansion of genomic and oncology diagnostic platforms.

Most recently, Dr. Meyyappan served as Global Chief Commercial Officer where he helped expand Menarini’s oncology diagnostics business and supported the commercial adoption of liquid biopsy and MRD-related diagnostic platforms.

Earlier in his career, he served as Chief Commercial Officer at Variantyx, where he led the global commercial launch of the Genomic Unity® whole-genome sequencing platform.

Dr. Meyyappan holds a Ph.D. in Cancer Biology from the University of Calgary and a Bachelor of Science in Biotechnology from the Rochester Institute of Technology.

Strengthening Global Commercialization Strategy

Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp., commented:

“Dr. Meyyappan brings extensive experience in scaling oncology diagnostics and genomics businesses globally. His expertise in commercial strategy, partnerships, and market development will be instrumental as Fidelion continues to build the infrastructure required to support the global adoption of next-generation diagnostic technologies.”

Mr. Tan continued:

“BioNexus Gene Lab Corp.’s strategic investment in Fidelion, together with our Southeast Asia commercialization rights for VitaGuard™, positions us to support the regional expansion of advanced precision oncology diagnostics. The addition of experienced commercial leadership represents an important step in advancing this strategy.”

Expanding Access to Precision Oncology Diagnostics

Dr. Meyyappan commented:

“Advances in genomics and liquid biopsy technologies are transforming how cancer is detected and monitored. Fidelion is building a platform to support the commercialization of innovative diagnostic technologies, and I look forward to working with the team to expand partnerships with healthcare providers, laboratories, and pharmaceutical companies globally.”

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging technology platforms. Through strategic investments, partnerships, and licensing arrangements, the Company supports the development and commercialization of next-generation healthcare technologies.

For more information, please visit

www.bionexusgenelab.com

Investor Relations

BioNexus Gene Lab Corp.

Email: IR@BIONEXUSGENELAB.COM

2

About Fidelion Diagnostics

Fidelion Diagnostics Pte. Ltd. is a precision diagnostics company focused on the global development and commercialization of advanced oncology testing technologies, including minimal residual disease (MRD) liquid biopsy assays.

For more information, please visit

www.fideliondx.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding commercialization initiatives, strategic partnerships, licensing arrangements, and the expected impact of executive leadership appointments.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect future results include market adoption of diagnostic technologies, regulatory developments, strategic partnership outcomes, commercialization execution, and other risks detailed in the Company’s filings with the Securities and Exchange Commission.

BioNexus Gene Lab Corp. undertakes no obligation to update any forward-looking statements except as required by law.

3

FAQ

What executive change did BioNexus Gene Lab Corp. (BGLC) announce?

BioNexus Gene Lab Corp. announced that Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion Diagnostics. He will oversee global commercial strategy and partnerships to support broader adoption of Fidelion’s advanced oncology diagnostic technologies, including the VitaGuard™ minimal residual disease platform.

What is Fidelion Diagnostics’ role in BioNexus Gene Lab Corp.’s strategy?

Fidelion Diagnostics serves as the international intellectual property and commercialization vehicle for the VitaGuard™ MRD technology developed by Tongshu Gene. It focuses on global development and commercialization of advanced oncology tests, enabling BioNexus to participate in precision oncology diagnostics markets outside Greater China.

What rights does BioNexus Gene Lab Corp. (BGLC) hold for VitaGuard™?

BioNexus Gene Lab Corp. holds exclusive commercialization rights for the VitaGuard™ MRD platform throughout Southeast Asia via a licensing arrangement with Fidelion Diagnostics. This positions the company to support regional expansion of next-generation precision oncology diagnostics across key Southeast Asian healthcare markets.

What experience does Dr. Muthu Meyyappan bring to Fidelion Diagnostics?

Dr. Muthu Meyyappan brings over 15 years of global leadership in precision oncology diagnostics, genomics, and liquid biopsy commercialization. He previously held senior commercial roles at Menarini Silicon Biosystems, Congenica, Variantyx, and QIAGEN, leading launches and international expansion of genomic and oncology diagnostic platforms.

How does minimal residual disease (MRD) testing fit BioNexus Gene Lab Corp.’s focus?

Minimal residual disease testing is described as one of the fastest-growing areas in precision oncology diagnostics. By investing in Fidelion and securing regional rights to VitaGuard™, BioNexus aligns itself with this growth segment, targeting earlier cancer detection and more personalized treatment monitoring using genomic technologies.

What did BioNexus CEO Sam Tan say about the Fidelion leadership appointment?

CEO Sam Tan said Dr. Meyyappan’s experience in scaling oncology diagnostics and genomics businesses globally will be instrumental as Fidelion builds infrastructure to support adoption of next-generation diagnostic technologies. He highlighted that BioNexus’ investment and Southeast Asia rights advance its precision oncology expansion strategy.

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 PRESS RELEASE 12.8 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 14.8 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 9.4 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB